Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

DMARD number, disease duration influence treatment outcomes in rheumatoid arthritis

09 Sep 2019

The previous use of multiple disease-modifying antirheumatic drugs (DMARDs) and disease duration appear to affect treatment outcomes in rheumatoid arthritis (RA) patients initiating adalimumab therapy, according to a posthoc analysis of two randomized controlled trials.

The analysis included 207 patients from DE019 and 67 patients from ARMADA who were treated with adalimumab plus methotrexate (MTX). Treatment response was evaluated at week 24 using the following outcomes: 28-joint Disease Activity Score based on C-reactive protein (DAS28[CRP]), Simplified Disease Activity Index (SDAI), Health Assessment Questionnaire Disability Index (HAQ-DI), and 20%/50%/70% improvement in American College of Rheumatology (ACR) responses.

Disease duration was ≤1 year for nine patients (4.3 percent), >1 to 5 years for 62 (30.0 percent), >5 to 10 years for 43 (20.8 percent) and >10 years for 93 (44.9 percent) in the DE019 cohort; and ≤5 years for 51 patients (76.1 percent) and >5 to 10 years for 16 (23.9 percent) in the ARMADA cohort. With respect to prior use of DMARDs, 75, 62 and 70 patients in DE019 used MTX plus 0–1, 2 and >2 DMARDs, respectively. The corresponding numbers of patients in ARMADA were 41, 13 and 13.

In DE019, a greater number of prior DMARDs (>2 vs 0–1) were linked to nominal improvements in DAS28(CRP) (–1.8 vs –2.2), SDAI (–22.1 vs –26.9) and HAQ-DI (–0.43 vs –0.64) at week 24. RA duration of >10 years vs <1 year was associated with higher HAQ-DI scores (1.1 vs 0.7) at week 24, but results for DAS28(CRP) and SDAI were mixed. A greater number of prior DMARDs and longer RA duration were both associated with lower ACR response rates at week 24.

The findings were consistent in ARMADA.

Taken together, the present data support recommendations to initiate without delay combination therapy with a biologic agent and MTX in patients with inadequate response to MTX monotherapy, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.